These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11266932)

  • 41. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients.
    Levy GA; Grant D; Paradis K; Campestrini J; Smith T; Kovarik JM
    Transplantation; 2001 Jan; 71(1):160-3. PubMed ID: 11211186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 43. 40-O -[2-Hydroxyethyl]rapamycin modulates human dendritic cell function during exposure to Aspergillus fumigatus.
    Bauer R; Mezger M; Blockhaus C; Schmitt AL; Kurzai O; Einsele H; Loeffler J
    J Basic Microbiol; 2012 Jun; 52(3):269-76. PubMed ID: 21780151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
    Nashan B
    Transplant Proc; 2001; 33(7-8):3215-20. PubMed ID: 11750380
    [No Abstract]   [Full Text] [Related]  

  • 45. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp.
    Laplante A; Demeule M; Murphy GF; Béliveau R
    Transplant Proc; 2002 Dec; 34(8):3393-5. PubMed ID: 12493480
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical pharmacokinetics of sirolimus.
    Mahalati K; Kahan BD
    Clin Pharmacokinet; 2001; 40(8):573-85. PubMed ID: 11523724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.
    De Simone P; Petruccelli S; Precisi A; Carrai P; Doria R; Menichetti F; Filipponi F
    Transplant Proc; 2007 Dec; 39(10):3500-1. PubMed ID: 18089420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood.
    Koster RA; Dijkers EC; Uges DR
    Ther Drug Monit; 2009 Feb; 31(1):116-25. PubMed ID: 19065123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS).
    Deters M; Kirchner G; Resch K; Kaever V
    Clin Chem Lab Med; 2002 Mar; 40(3):285-92. PubMed ID: 12005219
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sirolimus: a new immunosuppressant.
    Mukherjee T; Shah BV
    J Assoc Physicians India; 2005 Oct; 53():885-90. PubMed ID: 16459533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
    Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
    Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histopathologic impacts of everolimus introduction on kidney transplant recipients.
    Nakamura T; Ushigome H; Takata T; Nakao T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):630-4. PubMed ID: 25891700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
    Patsenker E; Schneider V; Ledermann M; Saegesser H; Dorn C; Hellerbrand C; Stickel F
    J Hepatol; 2011 Aug; 55(2):388-98. PubMed ID: 21168455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion.
    Paine MF; Leung LY; Lim HK; Liao K; Oganesian A; Zhang MY; Thummel KE; Watkins PB
    J Pharmacol Exp Ther; 2002 Apr; 301(1):174-86. PubMed ID: 11907172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Manipulation of the C(22)-C(27) region of rapamycin: stability issues and biological implications.
    Nelson FC; Stachel SJ; Eng CP; Sehgal SN
    Bioorg Med Chem Lett; 1999 Jan; 9(2):295-300. PubMed ID: 10021948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultra fast liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of cyclosporin A, tacrolimus, sirolimus, and everolimus in whole blood using deuterated internal standards for cyclosporin A and everolimus.
    Meinitzer A; Gartner G; Pilz S; Stettin M
    Ther Drug Monit; 2010 Feb; 32(1):61-6. PubMed ID: 20010460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
    Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
    Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe psoriasis treated with a new macrolide: everolimus.
    Frigerio E; Colombo MD; Franchi C; Altomare A; Garutti C; Altomare GF
    Br J Dermatol; 2007 Feb; 156(2):372-4. PubMed ID: 17223881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppressants produced by Streptomyces: evolution, hygiene hypothesis, tumour rapalog resistance and probiotics.
    Bolourian A; Mojtahedi Z
    Environ Microbiol Rep; 2018 Apr; 10(2):123-126. PubMed ID: 29377607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.